as coinfection has been linked to deterioration of both disease states. The objective of this review article is to highlight the current literature on drug-drug interactions between HIV and HCV treatments. The management of the treatment of coinfection patients has been covered extensively in numerous other publications. and ribavirin (RBV) for a duration of 48 weeks or longer. However, this treatment has many limitations including the low sustained virologic response rate, long duration of treatment, and difficult adverse event profiles.
Keywords
The landscape for HCV treatment is dynamic and rapidly changing. To date, there are four classes of direct-acting antiviral agents (DAA).
These are NS3/4A protease inhibitors, NS5A inhibitors, NS5B RNA-dependent polymerase inhibitors, and non-nucleoside polymerase inhibitors. Each class differs in their genotype coverage, treatment status (e.g., treatmentnaïve, relapsers, nonresponders), and coinfected patient populations.
The development of early DAAs (NS3/4A protease inhibitors; telaprevir, boceprevir) instigated a change deviating away from the previous gold-standard regimen. The two firstgeneration NS3/4A protease inhibitors (PI), telaprevir and boceprevir, were approved in 2011 for the treatment of genotype 1-infected patients in combination with PEG-IFN and RBV [2] . Simeprevir, a second-generation NS3/4A PI, was later approved with the same regimen in patients with compensated liver disease.
Recently, a nucleotide analog, sofosbuvir, received FDA approval for the treatment of HCV genotypes 1-6. Sofosbuvir has completely changed the basis of the treatment of HCV. For the first time in the history of this disease, a non-interferon-based regimen was approved as first line for the treatment of HCV. Depending on the hepatitis C genotype, an all-oral regimen was also made possible. A combination product consisting of ledipasvir, aNS5A inhibitor, and sofosbuvir (Harvoni Ò ) was the first once-daily single tablet regimen to treat chronic hepatitis C genotype 1 and 4 infection in adults. An additional combination product consisting of ombitasvir, an NS5A inhibitor, paritaprevir, an NS3/4A protease inhibitor, dasabuvir, an NS5B palm polymerase inhibitor, and ritonavir, a cytochrome P450 3A inhibitor, was also recently approved.
Highly active antiretroviral therapy (HAART)
is the mainstay therapy for HIV. [4]. Seven million persons worldwide are infected with both HIV and HCV [5] . HIV/ HCV coinfection is associated with higher rates of liver fibrosis, cirrhosis, hepatocellular carcinoma, and overall mortality compared to either infection alone [6] . It has been established that coinfected patients who are treated optimally for HCV have improved clinical outcomes and survival [7] . However, drug interactions among HIV and HCV agents limit the appropriate treatment of either disease state, leading to severe complications and even early deaths in this patient population. This review is designed to summarize the current literature on drug interactions between HCV and HIV treatment regimens. 
METHODS

Relevant
RESULTS
This article reviews drug interactions between established HCV and HIV medications. Drugs pending approval were not included in this review because of lack of available data.
Summaries of the drug interactions and their mechanisms are presented in Tables 1 and 2 . PEG-IFN and RBV [9] [10] [11] . Upon oral administration, SOF is rapidly converted into the GS-331007 metabolite, which is dominant and accounts for C90% drug-related exposure in the body [8] . SOF is responsible only for approximately 4% drug exposure in the body.
It is a substrate of drug transporter p-glycoprotein (P-gp) and breast cancerresistant protein (BCRP) [8] . However, P-gp and BCRP do not affect GS-331007, the The direction of the arrow (: = increase, ; = decrease, $ = no change) indicates the direction of the change in drug concentration dominant metabolite [8] . Agents that induce P-gp in the intestine (e.g., rifampin) may decrease SOF plasma concentrations, reducing the therapeutic efficacy of SOF and thereby increasing the patient's risk of HCV exacerbations [8] . On the other hand, coadministration of SOF with drugs that inhibit P-gp (e.g., quinidine) and/or BCRP (e.g., elacridar) may increase the SOF plasma concentration without increasing the GS-331007 plasma concentration [8] . Accordingly, SOF may be coadministered with P-gp and/or BCRP inhibitors.
Sofosbuvir Drug-Drug Interactions with HIV Medications
Tipranavir (TPV) is a PI that is indicated for treatment of resistant HIV genotype-1 infected patients in combination with other antiretroviral agents [12] . TPV is a P-gp inhibitor and therefore may increase the plasma concentration of SOF, a P-gp substrate.
No studies were found to support this drug interaction; however, the American Association for the Study of Liver Diseases (AASLD) guidelines recommends avoiding the use of SOF if the patient is concomitantly taking TPV [13] . The hepatic cytochrome (CYP) P450 enzyme complex does not metabolize SOF [8] .
A drug interaction study with efavirenz (EFV), tenofovir (TDF), emtricitabine (FTC), rilpivirine (RPV), darunavir/ritonavir (DRV/r), and raltegravir (RAL) in noninfected individuals identified no clinically significant interactions [14] . Since no interactions with cytochrome P450 enzymes were identified, SOF is an ideal option for patients with HIV/HCV coinfection.
Compared to other protease inhibitor medications, simeprevir (SIM) is a relatively small macrocyclic drug that targets and selectively inhibits HCV NS3/4A serine protease, thereby blocking the enzyme that enables HCV to replicate in host cells [15] . It is FDA approved for the treatment of genotype 1 chronic hepatitis C in combination with PEG-IFN and RBV. SIM is a competitive, reversible, macrocyclic, noncovalent inhibitor that has improved affinity and selectivity for protein targets when compared to telaprevir (TEL) and BOC [15, 16] . SIM is a weak inhibitor of CYP 1A2 activity and intestinal CYP 3A4 activity, but does not affect hepatic CYP 3A4 activity. Furthermore, SIM inhibits OATP1B1/3 and P-gp transporters. Coadministration of SIM with drugs that are substrates for CYP 3A4 (e.g., amiodarone), OATP1B1/3 (e.g., methotrexate) and P-gp (e.g., digoxin) transport may result in increased plasma concentrations of such drugs.
In addition, SIM is also a substrate for CYP 3A4
and can therefore be the subject of drug-drug interactions with moderate or strong inhibitors 
Ledipasvir/Sofosbuvir Drug-Drug Interactions with HIV Medications
The drug interactions with SOF as discussed previously apply to this combination as well.
LDV is an inhibitor of the drug transporters P-gp and BCRP and has the potential to increase intestinal absorption of coadministered substrates for these transporters [22] . Coadministration of LDV/SOF with TPV with RTV is expected to decrease the concentration of LDV and SOF, leading to a reduced therapeutic effect of LDV/SOF. According to prescribing information, coadministration of LDV/SOF with TPV/RTV is not recommended [22] .
According to the package insert, no clinical drug interactions have been observed or are expected when LDV/SOF is used with abacavir (ABC), ATV/r, DRV/r, EFV, FTC, lamivudine (3TC), RAL, RPV, or TDF antiretroviral agents [22] . [44] .
Boceprevir (Victrelis
PTV has been studied as part of the entire regimen with boosted HIV protease inhibitors atazanavir, darunavir, and lopinavir in noninfected individuals. There were minimal changes to the maximum concentration (C max ) and AUC for these antiretroviral drugs, although trough concentrations were increased for atazanavir and lopinavir and decreased for darunavir. Although paritaprevir C max and AUC values were minimally to moderately increased, no dose adjustment has been recommended [45] . Because 100 mg of ritonavir is coformulated with paritaprevir and ombitasvir, the total dose of ritonavir must be carefully considered when using ritonavircontaining antiretroviral regimens.
Coadministration with ritonavir-boosted lopinavir would result in 300 mg daily of ritonavir. This dose has been associated with adverse gastrointestinal effects; as a result, this combination is not recommended.
In noninfected volunteers, when OBV/PTV/ r ? DAV was combined with efavirenz, emtricitabine, and tenofovir, clinically significant gastrointestinal and neurologic adverse events occurred [46] . Elevations of alanine aminotransferase levels occurred when administered with efavirenz; therefore, coadministration with efavirenz is not recommended [46] . When the entire regimen was combined with rilpivirine, exposures to rilpivirine were substantially increased [46] . A higher concentration of rilpivirine has the potential to prolong the QT interval; therefore, rilpivirine should not be used with OBV/PTV/r plus DAV and RBV. 
